View in EDS HTML Full Text PDF Full Text

Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.

Saved in:
Bibliographic Details
Title: Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.
Authors: Schapira, A. H. V., Barone, P., Hauser, R. A., Mizuno, Y., Rascol, O., Busse, M., Debieuvre, C., Fraessdorf, M., Poewe, W.
Source: European Journal of Neurology. Jan2013, Vol. 20 Issue 1, p50-56. 7p. 2 Diagrams, 3 Charts, 1 Graph.
Subjects: Drug dosage, Surveys, Parkinson's disease treatment, Blind experiment, Pramipexole, Placebos, Chronic diseases
Abstract: Background and purpose: In chronic diseases including Parkinson's disease (PD), complex pharmacotherapy dosing schedules are reported to reduce adherence, perhaps leading to less-effective symptom control and, in PD, more erratic stimulation of dopamine receptors. However, blinded clinical-trial designs preclude direct comparisons of adherence to various schedules. Methods: In two double-blind (DB) studies of early PD and one of advanced PD, subjects received three-times-daily (t.i.d.) pramipexole or placebo. In open-label (OL) extensions, subjects took extended-release, once-daily (q.d.) pramipexole. At 24 or 32 OL weeks, q.d. versus t.i.d. dosing preference was surveyed by questionnaire. Results: Of 590 DB-trial completers with early PD, 511 entered the OL extension. Of 374 survey respondents, 94.4% preferred q.d. dosing (72.2% of them found it 'very much more convenient' and 27.8%'more convenient'), 2.7% preferred t.i.d., and 2.9% chose 'no difference'. Of 465 DB-trial completers with advanced PD, 391 entered its OL extension. Of 334 survey respondents, 88.9% preferred q.d. dosing (59.9% of them found it 'very much more convenient' and 40.1%'more convenient'), 5.7% preferred t.i.d., and 5.4% chose 'no difference'. Results excluding DB-placebo recipients were highly similar. Conclusions: In this first direct comparison of patient preference for q.d. versus t.i.d. dopamine-agonist dosing, patients with early or advanced PD had a strong preference for q.d. rather than t.i.d. pramipexole. The high proportion of advanced-PD patients declaring this preference indicates that it does not depend on whether a patient is taking concomitant PD medications dosed more frequently than q.d. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 84506450
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Schapira%2C+A%2E+H%2E+V%2E%22">Schapira, A. H. V.</searchLink><br /><searchLink fieldCode="AR" term="%22Barone%2C+P%2E%22">Barone, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Hauser%2C+R%2E+A%2E%22">Hauser, R. A.</searchLink><br /><searchLink fieldCode="AR" term="%22Mizuno%2C+Y%2E%22">Mizuno, Y.</searchLink><br /><searchLink fieldCode="AR" term="%22Rascol%2C+O%2E%22">Rascol, O.</searchLink><br /><searchLink fieldCode="AR" term="%22Busse%2C+M%2E%22">Busse, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Debieuvre%2C+C%2E%22">Debieuvre, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Fraessdorf%2C+M%2E%22">Fraessdorf, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Poewe%2C+W%2E%22">Poewe, W.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Jan2013, Vol. 20 Issue 1, p50-56. 7p. 2 Diagrams, 3 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+dosage%22">Drug dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Surveys%22">Surveys</searchLink><br /><searchLink fieldCode="DE" term="%22Parkinson's+disease+treatment%22">Parkinson's disease treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Blind+experiment%22">Blind experiment</searchLink><br /><searchLink fieldCode="DE" term="%22Pramipexole%22">Pramipexole</searchLink><br /><searchLink fieldCode="DE" term="%22Placebos%22">Placebos</searchLink><br /><searchLink fieldCode="DE" term="%22Chronic+diseases%22">Chronic diseases</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: In chronic diseases including Parkinson's disease (PD), complex pharmacotherapy dosing schedules are reported to reduce adherence, perhaps leading to less-effective symptom control and, in PD, more erratic stimulation of dopamine receptors. However, blinded clinical-trial designs preclude direct comparisons of adherence to various schedules. Methods: In two double-blind (DB) studies of early PD and one of advanced PD, subjects received three-times-daily (t.i.d.) pramipexole or placebo. In open-label (OL) extensions, subjects took extended-release, once-daily (q.d.) pramipexole. At 24 or 32 OL weeks, q.d. versus t.i.d. dosing preference was surveyed by questionnaire. Results: Of 590 DB-trial completers with early PD, 511 entered the OL extension. Of 374 survey respondents, 94.4% preferred q.d. dosing (72.2% of them found it 'very much more convenient' and 27.8%'more convenient'), 2.7% preferred t.i.d., and 2.9% chose 'no difference'. Of 465 DB-trial completers with advanced PD, 391 entered its OL extension. Of 334 survey respondents, 88.9% preferred q.d. dosing (59.9% of them found it 'very much more convenient' and 40.1%'more convenient'), 5.7% preferred t.i.d., and 5.4% chose 'no difference'. Results excluding DB-placebo recipients were highly similar. Conclusions: In this first direct comparison of patient preference for q.d. versus t.i.d. dopamine-agonist dosing, patients with early or advanced PD had a strong preference for q.d. rather than t.i.d. pramipexole. The high proportion of advanced-PD patients declaring this preference indicates that it does not depend on whether a patient is taking concomitant PD medications dosed more frequently than q.d. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=84506450
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/j.1468-1331.2012.03712.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 50
    Subjects:
      – SubjectFull: Drug dosage
        Type: general
      – SubjectFull: Surveys
        Type: general
      – SubjectFull: Parkinson's disease treatment
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Pramipexole
        Type: general
      – SubjectFull: Placebos
        Type: general
      – SubjectFull: Chronic diseases
        Type: general
    Titles:
      – TitleFull: Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schapira, A. H. V.
      – PersonEntity:
          Name:
            NameFull: Barone, P.
      – PersonEntity:
          Name:
            NameFull: Hauser, R. A.
      – PersonEntity:
          Name:
            NameFull: Mizuno, Y.
      – PersonEntity:
          Name:
            NameFull: Rascol, O.
      – PersonEntity:
          Name:
            NameFull: Busse, M.
      – PersonEntity:
          Name:
            NameFull: Debieuvre, C.
      – PersonEntity:
          Name:
            NameFull: Fraessdorf, M.
      – PersonEntity:
          Name:
            NameFull: Poewe, W.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2013
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1